NFA
NAGE

Nationwide Fund Advisors’s Niagen Bioscience NAGE Stock Holding History

Nationwide Fund Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-18,670
Closed -$50K – 3273
2017
Q1 		$50K Hold
18,670
– – ﹤0.01% 2983
2016
Q4 		$62K Hold
18,670
– – ﹤0.01% 2977
2016
Q3 		$56K Hold
18,670
– – ﹤0.01% 3033
2016
Q2 		$77K Buy
+18,670
New +$88.3K ﹤0.01% 3003

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nationwide Fund Advisors's NAGE Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Niagen Bioscience (NAGE) in Q2 2017, closing a stake of 18,670 shares — an estimated $50K sold.

Nationwide Fund Advisors first reported a position in NAGE in Q2 2016 and held it in 4 quarters. The position peaked at $77K in Q2 2016. 46 funds tracked by Wall St. Rank hold NAGE as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Niagen Bioscience position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 18,670 Niagen Bioscience shares in Q2 2017, an estimated $50K.
  • Nationwide Fund Advisors first reported a position in Niagen Bioscience in Q2 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Niagen Bioscience position peaked at $77K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.